Press Releases

Press Releases

Octagos Health announces strategic investments in product, AI and talent

Following its recent $43 million Series B funding, the company is expanding its data integration capabilities to include a broader range of devices, including wearables, heart failure monitoring, and remote patient monitoring.

Elutia announces first patient implant of EluPro, the world’s first drug-eluting bioenvelope for cardiac pacemakers and neurostimulators

The procedure was performed in Greenville, North Carolina.

2023 Hearst Health Prize - AI for Incidental CAC

Congratulations to Stanford Medicine on winning the 2023 Hearst Health Prize for its artificial intelligence solution that helps identify patients at risk for heart attack by scoring incidental coronary artery calcium (CAC) on non-gated chest CTs.

DASI Simulations' PrecisionTAVI gets CMS Hospital Outpatient Billing Code

Predictive model generation for pre-planning a cardiac procedure now reimbursable by Medicare at approximately $1,000 per model

 

Echo IQ's breakthrough research on cardiovascular health continues with unveiling of AI-driven aortic stenosis and mitral regurgitation detection results at ESC 2023 Congress

Late-Breaking Science sessions reveal revolutionary findings on severe aortic stenosis and mild-to-severe mitral regurgitation identification through innovative AI technology.

 

Keystone Perfusion Services, PC recognized for life-saving contribution during COVID-19 pandemic, secures fifth consecutive year on Inc. 5000 list
| Submitted by: Keystone Perfusion Services, PC

The company's multifaceted healthcare staffing solutions play a pivotal role in transforming patient care and elevating industry standards.

 

Corazon and the Society for Cardiovascular Angiography and Interventions announce partnership

The agreement formally endorses Corazon’s cardiovascular accreditation.

Arineta announces SpotLight Duo, the world’s first dedicated cardiovascular and thoracic CT system

Arineta Cardio Imaging is excited to announce the FDA 510(k) clearance of the SpotLight and SpotLight Duo family of cardiovascular CT scanners.

Study Confirms Ultromics’ AI Can Improve HFpEF Detection Using a Single Echocardiogram View

 

Researchers and engineers at Mayo Clinic and Ultromics developed technology that can detect HFpEF using a single A4C echocardiogram clip, to help clinicians detect a complex form of heart failure easily and accurately. 

 

Cassling connects cardiologists with revolutionary AI software

The Midwest company will begin offering EchoSolv, an artificial intelligence clinical decision support platform designed to help detect severe aortic stenosis, to providers throughout the country.

 

DASI Simulation’s Precision TAVI earns FDA clearance
| Submitted by: DASI Simulations

Precision TAVI is the first FDA-approved predictive modeling tool for medical teams planning TAVR procedures.

 

 

RecoverRite®, American College of Cardiology Collaborate to Change the Face of Cardiovascular Patient Education

RecoverRite’s Online Heart Learning Center to feature ACC’s CardioSmart patient tools and resources.

Study shows PulseAI’s deep learning algorithm outperforms the Apple Watch ECG algorithm in detecting atrial fibrillation

PulseAI, a leader in the development of cutting-edge AI-powered ECG software, has released the results of a clinical study that has shown the superiority of its deep learning AI over the Apple Watch ECG algorithm in the detection of atrial fibrillation.

 

$20M gift announced by the Rooney Foundation in support of enhanced cardiac care at NCH

NAPLES, Fla. – February 20, 2023   The NCH Healthcare System is proud to announce a $20 million naming gift from the Rooney Foundation, which is the philanthropic arm of the former U.S. Representative for Florida's 19th congressional district and his wife, Francis and Kathleen Rooney.  In recognition of increasing their $8 million pledge announced last July, the entire cardiac program across NCH Healthcare System will be renamed “The Rooney Heart Institute.”

NCH announces second historic gift in as many weeks totaling a record $40M in support of enhanced care

NAPLES, Fla. – February 21, 2023   On the heels of our historic $20 Million gift announcement made last week, NCH is proud to announce yet a second $20 million naming gift in as many weeks from Diana and Don Wingard.  This generous gift will provide the necessary funds to ensure that the NCH Stroke program continues to provide the highest level of care and treatment to patients in Southwest Florida.  Additionally, in recognition of the extraordinary pledge, the entire stroke program across NCH will be renamed the “Wingard Stroke Institute.”

Patient Image Exchange puts patients 'in the driver’s seat'

When using this service, patients have the ability to upload and share data without limitations. From radiology CDs to PDFs or JPG files, patients can use their smartphone connected to the Patient Image Exchange app and upload images, share lab results, immunizations records, nurses’ notes, dental images and much more.

 

Ancora Heart appoints David J. Tucker as chief financial officer

Ancora Heart has hired senior financial leader David J. Tucker as its chief financial officer. This is the company's second C-suite hire in 2022, following the addition of Mark Miles as chief commercial officer in June.

Geneticure presents data successfully identifying responders and non-responders to renal denervation using genetic screening

Geneticure, a global leader in the genetic variability of response to hypertension treatments, presented data at the 2022 American Heart Association Scientific Sessions meeting from a recent clinical study in which they were able to successfully predict patients who will respond to renal denervation (RDN). In addition, the Geneticure test for renal denervation also identified patients with an increase in blood pressure, following the procedure.

Cardiac Insight Comments on CMS Announcement of National Payment Rates for Long-Term Continuous ECG (LT-ECG) Monitoring in 2023

Long-awaited milestone gives physicians and their patients greater access to prescription cardiac arrhythmia detection solutions, including the company’s Cardea SOLO™ ECG System

World's Smallest Pacemaker, Medtronic Micra® TPS, Meets Global Clinical Trial's Safety and Effectiveness Endpoints

In the largest clinical data presentation ever of transcatheter pacing patients, Medtronic plc (NYSE: MDT) today announced that the Medtronic Micra® Transcatheter Pacing System (TPS) was successfully implanted in nearly all patients in the trial - 99.2 percent - and met its safety and effectiveness endpoints with wide margins.

MyoKardia Announces Presentations at American Heart Association Scientific Sessions 2015

MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced presentations at the American Heart Association (AHA) Scientific Sessions 2015, being held November 7-11 in Orlando, Fla.

IN.PACT Admiral Drug-Coated Balloon Cost-Effectiveness Study and Global Study Results of In-Stent Restenosis Population Highlighted in Late Breaking Clinical Trials at VIVA 2015

Medtronic plc (NYSE: MDT) adds to the robust data for its IN.PACT® Admiral® drug-coated balloon (DCB)  with the presentation of both its formal cost-effectiveness analysis from the U.S. cohort of the IN.PACT SFA Trial and clinical results from the in-stent restenosis cohort data from Medtronic's IN.PACT Global Study. 

Tryton Medical Files Pre-Market Approval Application with US FDA for Tryton Side Branch Stent

Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that it has filed the final module of its Pre-Market Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the Tryton Side Branch Stent.

Sorin Group Starts First Randomized, Controlled Trial Comparing the Perceval Sutureless Valve to Standard Bioprostheses

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, today announced the initiation of PERSIST-AVR (Perceval Sutureless Implant Vs Standard Aortic ValveReplacement), the first international, prospective, post-market randomized multi-center trial evaluating the Perceval sutureless aortic valve compared to standard sutured bioprostheses in patients with aortic valve disease.

Medtronic Receives CE Mark for New Single-Chamber ICDs That Can Detect Atrial Fibrillation

Medtronic plc (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for the Visia AF(TM) and Visia AF MRI(TM) SureScan® single-chamber implantable cardioverter defibrillators (ICDs), which can detect and monitor new onset, asymptomatic, and previously undiagnosed atrial fibrillation (AF).

Medtronic Partners with Local Organizations and Minnesota Department of Health to Advance Health Equity in Minnesota

Medtronic (NYSE: MDT) today announced that Pillsbury United Communities, Regions Hospital Foundation and the HealthFinders Collaborative have been selected by Medtronic Philanthropy to implement the HealthRise U.S. program in Minnesota.

Abiomed's Impella(R) Technology Showcased at TCT 2015 With Over 25 Presentations in the Scientific Sessions

Abiomed Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announces that there are currently over 25 presentations potentially featuring the Impella line of heart pumps, scheduled in the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific meeting, scheduled from October 11 - 15, at the Moscone Convention Center in San Francisco.

FORTITUDE Clinical Findings Presented at Transcatheter Cardiovascular Therapeutics Meeting

Amaranth Medical, a privately held medical device company, announced that enrollment has successfully concluded in its multi-center, international CE Mark clinical trials: MEND-II and RENASCENT-I, which assessed Amaranth's FORTITUDE(R) sirolimus-eluting bioresorbable scaffold (BRS) in patients with symptomatic coronary artery disease. 

Medtronic CoreValve® System Demonstrates Excellent Clinical Outcomes in First Report of 'Real-World' U.S. Experience

Medtronic plc (NYSE: MDT) today released the first CoreValve® Transcatheter Aortic Valve Replacement (TAVR) System outcomes data using CoreValve data from The Society of Thoracic Surgeons and American College of Cardiology (STS/ACC) Transcatheter Valve Therapy (TVT) Registry. 

Corindus VasCular Robotics and Mayo Clinic Launch vascular robotic program to Research Physician safety

Corindus Vascular Robotics (NYSE MKT: CVRS) today announced the formation of a joint robotic-assisted percutaneous coronary intervention (PCI) research and clinical program. 

3D Systems Expands Product Lines for Cardiology Training and Surgical Planning

3D Systems (NYSE:DDD) announced today the introduction of advanced cardiology training modules for the ANGIO Mentor(TM) VR simulator, together with a cardiovascular anatomical model product line that allows visualization of complex cardiovascular anatomy.

Stereotaxis Introduces Respiratory Compensation Feature for Remote Magnetic Navigation Procedures

Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the worldwide launch of Respiratory Compensation, a new software feature of the Company’s Niobe® remote magnetic navigation system.

Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants

Medtronic plc (NYSE: MDT) unveiled today new data from the first implants of its novel Drug-Filled Stent (DFS) at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

HBR, NEJM and Medtronic Launch New Initiative Driving Discussion on Value-Based Healthcare

As communities around the world increasingly adopt programs based on value-based healthcare principles, thought-leading perspectives on how to improve patient outcomes while addressing cost in the healthcare systems will be the focus of the new Harvard Business Review (HBR) Insight Center, exclusively sponsored by Medtronic plc (NYSE: MDT).

Medtronic Completes Acquisition of Twelve, Inc.

Medtronic plc (NYSE: MDT) today announced that it has completed the acquisition of Twelve, Inc. ("Twelve"), a privately-held medical device company based in Redwood City, CA, focused on the development of a transcatheter mitral valve replacement (TMVR) device.

MiniMed Connect Now Available from Medtronic for Smartphone Access to Personal Diabetes Data

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. commercial availability of MiniMed Connect, the first and only product to enable people with diabetes to discreetly and conveniently view their insulin pump and continuous glucose monitoring (CGM) information on a smartphone.

Medtronic Acquires Lazarus Effect

Medtronic plc  (NYSE:MDT) today announced it has acquired Lazarus Effect, a Campbell, Calif.-based and privately-held medical device company focused on acute ischemic stroke products that facilitate the capture and removal of clots.

Medtronic Launches Arc(TM) Support Catheter Series in U.S. for Treatment of Acute Ischemic Stroke

Medtronic plc (NYSE: MDT) today announced the U.S. launch of the Arc(TM) support catheter, the most navigable, 6F tapered support catheter available.

Bankruptcy Judge Approves Sale of HDL, Inc. to True Health Diagnostics, LLC

United States Bankruptcy Judge Kevin R. Huennekens today gave final approval for the $37.1 million sale of substantially all of the business assets of Health Diagnostic Laboratory Inc. (HDL, Inc.) to True Health Diagnostics, LLC.

Medtronic First to Receive FDA Approval for MR-Conditional Implantable Cardioverter Defibrillator System

Medtronic plc (NYSE: MDT) today announced that it has received the first U.S. Food and Drug Administration (FDA) approval for an implantable cardioverter defibrillator (ICD) system for use with magnetic resonance imaging (MRI) scans.